Apnimed
NASDAQ: APMDCambridge, US · Founded 2017 · Delaware corporation · 2 known investors
Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients. It is a clinical-stage pharmaceutical company focused on sleep apnea.
BiotechDigital HealthHealthtech
Founders & leadership
Apnimed was founded in 2017 by Lawrence G. Miller.
LG
Lawrence G. MillerFounder
DM
Dennis MolnarExecutive
BW
Barry WohlChief Business Officer
KM
Ketan MehtaHead of Product and Engineering, Connected Wearables
RF
Ron FarquharNamed on SEC filing
GC
Gerald ChanNamed on SEC filing
Board
KL
Kevin LindBoard director
CD
Chris DimitropoulosBoard director
FB
Francois BeaubienBoard director
IC
Isaac ChengBoard director
PF
Paul FonteyneBoard director
GS
Gary SenderBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$284.3M disclosed across 8 of 9 rounds · 2018–2026
▶$25MraisedMar 2026 · 2 investors · PharmaceuticalsRule 506(b)
▶$25MraisedMar 2026 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence G. MillerExecutive Officer, Director
- Paul FonteyneDirector
- Dennis MolnarExecutive Officer
- Barry WohlExecutive Officer
- Joseph C. AvelloneDirector
- Francois BeaubienDirector
- Chris DimitropoulosDirector
- Kevin LindDirector
- Isaac ChengDirector
- Gary SenderDirector
- Ramzi BenamarExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedDec 2025 · 7 investors · PharmaceuticalsRule 506(b)
▶$35MraisedDec 2025 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin LindDirector
- Ramzi BenamarExecutive Officer
- Dennis MolnarExecutive Officer
- Barry WohlExecutive Officer
- Chris DimitropoulosDirector
- Francois BeaubienDirector
- Paul FonteyneDirector
- Gary SenderDirector
- Lawrence G. MillerExecutive Officer, Director
- Isaac ChengDirector
- Joseph C. AvelloneDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.5MraisedApr 2025 · 3 investors · PharmaceuticalsRule 506(b)
▶$16.5MraisedApr 2025 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul FonteyneDirector
- Barry WohlExecutive Officer
- Kevin LindDirector
- Gary SenderDirector
- Dennis MolnarExecutive Officer
- Joseph C. AvelloneDirector
- Lawrence G. MillerExecutive Officer, Director
- Chris DimitropoulosDirector
- Francois BeaubienDirector
- Isaac ChengDirector
- Offering amount
- $16.5M
- Amount sold
- $16.5M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$37.5MofferedNov 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$37.5MofferedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence G. MillerExecutive Officer, Director
- Francois BeaubienDirector
- Michael RogersExecutive Officer
- Dennis MolnarExecutive Officer, Director
- Isaac ChengDirector
- Barry WohlExecutive Officer
- Paul FonteyneDirector
- Joseph C. AvelloneDirector
- Chris DimitropoulosDirector
- Offering amount
- $37.5M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$79.7MraisedDec 2022 · 6 investors · PharmaceuticalsRule 506(b)
▶$79.7MraisedDec 2022 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Barry WohlExecutive Officer
- Chris DimitropoulosDirector
- Lawrence G. MillerExecutive Officer, Director
- Michael RogersExecutive Officer
- Ruoxi HuDirector
- Dennis MolnarExecutive Officer, Director
- Stefan LarsonDirector
- Isaac ChengDirector
- Joseph C. AvelloneDirector
- Offering amount
- $79.7M
- Amount sold
- $79.7M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$62.5MraisedNov 2022 · 14 investors · PharmaceuticalsRule 506(b)
▶$62.5MraisedNov 2022 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rosy HuDirector
- Barry WohlExecutive Officer
- Michael RogersExecutive Officer
- Chris DimitropoulosDirector
- Joseph C. AvelloneDirector
- James GaleotaDirector
- Isaac ChengDirector
- Lawrence G. MillerExecutive Officer, Director
- Dennis MolnarExecutive Officer, Director
- Stefan LarsonDirector
- Offering amount
- $62.5M
- Amount sold
- $62.5M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$25MraisedMar 2021 · 3 investors · PharmaceuticalsRule 506(b)
▶$25MraisedMar 2021 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence G. MillerExecutive Officer, Director
- Dennis MolnarExecutive Officer, Director
- Joseph C. AvelloneDirector
- James GaleotaDirector
- Gerald ChanDirector
- Barry WohlExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$15MraisedApr 2020 · 1 investors · Other Health CareRule 506(b)
▶$15MraisedApr 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ron FarquharDirector
- Lawrence G. MillerExecutive Officer, Director
- Gerald ChanDirector
- Barry WohlExecutive Officer
- Joseph AvelloneDirector
- Dennis MolnarExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapFox News30 shared keywordsFox News is a news and media organization publishing coverage of U.S. and world politics, business, entertainment, sports, and weather. It offers written articles and video content, including a streaming subscription service, for a general American audience.
Medscape29 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Companies competing with Apnimed for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Apnimed do?
- Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients. It is a clinical-stage pharmaceutical company focused on sleep apnea.
- Who founded Apnimed?
- Apnimed was founded by Lawrence G. Miller in 2017.
- Who are Apnimed's investors?
- Apnimed's investors include Alpha Wave Global, HEALTHCARE ROYALTY PARTNERS.
- How much funding has Apnimed raised?
- Apnimed has disclosed $284.3M raised across 8 of its 9 known rounds.
- Where is Apnimed headquartered?
- Apnimed is headquartered in Cambridge, US.